InvestorsHub Logo

DewDiligence

10/25/18 4:57 PM

#46 RE: DewDiligence #43

SNDX -21%/AH on PFS failure in HR+/HER2- breast cancer:

https://finance.yahoo.com/news/syndax-host-conference-call-phase-200500374.html

The trial continues to test for statsig OS every six months until Nov 2019.